Open Topic Search

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.

If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

Displaying 51 - 60 of 74 results
  1. PA-16-342 : Methods Development in Natural Products Chemistry (R41/R42)

    Release Date: 06-23-2016Open Date: 08-05-2016 Due Dates: Multiple Close Date: 04-05-2019

    Background Natural products are essential sources of medicines.  The World Health Organization estimates that ~80% of the world’s population relies on traditional medicines made from natural products. The modern pharmaceutical industry is also dependent on plant-based medicines, with as much as 50% of all drugs based on natural products or derived from a natural product origin. Clearly, nat ...

    STTR Department of Health and Human Services
  2. PAR-16-271 : NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44)

    Release Date: 05-18-2016Open Date: 08-12-2016 Due Dates: Multiple Close Date: 05-13-2019

    Purpose This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials. A clinical trial is defined by NIH as: “A research study in which one or more human subjects are prospectively assigned to one or more interventions (which may ...

    SBIR Department of Health and Human Services
  3. PAR-16-376 : T2 Translational Research on Aging: Small Business Innovation Awards (R43/R44)

    Release Date: 07-22-2016Open Date: 12-05-2016 Due Dates: Multiple Close Date: 09-05-2019

    Background The involvement of small businesses in translational aging research could hasten the pace at which scientific advances are transformed into commercial products to improve or maintain the health and functional independence of older adults.  Therefore, this funding opportunity announcement (FOA) is intended to support innovative research conducted by small businesses to advance the a ...

    SBIR Department of Health and Human Services
  4. PAR-16-375: T1 Translational Research on Aging: Small Business Innovation Awards (R43/R44)

    Release Date: 07-22-2016Open Date: 12-05-2016 Due Dates: Multiple Close Date: 09-05-2019

    Background The involvement of small businesses in translational aging research could hasten the pace at which scientific advances are transformed into commercial products to improve or maintain the health and functional independence of older adults.  Therefore, this funding opportunity announcement (FOA) is intended to support innovative research conducted by small businesses to advance the a ...

    SBIR Department of Health and Human Services
  5. PAR-17-034: NIDDK Exploratory Clinical Trials for Small Business (R44)

    Release Date: 10-27-2016Open Date: 12-05-2016 Due Dates: Multiple Close Date: 09-05-2019

    Purpose This Funding Opportunity Announcement (FOA) supports applications from Small Business Concerns (SBCs) for exploratory clinical trials that contribute to the justification for a future trial to establish definitive efficacy (such as a Phase 3 clinical trial or a pivotal device trial). This includes Phase 1 and 2 clinical studies of drugs, biologics and biotechnology products, feasibility st ...

    SBIR Department of Health and Human Services
  6. PAR-17-036 : Platform Delivery Technologies for Nucleic Acid Therapeutics (R41/R42)

    Release Date: 10-27-2016Open Date: 12-05-2016 Due Dates: Multiple Close Date: 09-05-2019

    Background There are thousands of rare diseases, and a substantial fraction of these are monogenic disorders, resulting from mutations in a single gene. For such diseases, nucleic acid therapeutics are of potentially broad therapeutic potential. It is important to note, however, that the therapeutic potential of nucleic acids is not limited to rare monogenetic diseases, but also includes more comm ...

    STTR Department of Health and Human Services
  7. PAR-17-035 : Platform Delivery Technologies for Nucleic Acid Therapeutics (R43/R44)

    Release Date: 10-27-2016Open Date: 12-05-2016 Due Dates: Multiple Close Date: 09-05-2019

    Background There are thousands of rare diseases, and a substantial fraction of these are monogenic disorders, resulting from mutations in a single gene. For such diseases, nucleic acid therapeutics are of potentially broad therapeutic potential. It is important to note, however, that the therapeutic potential of nucleic acids is not limited to rare monogenetic diseases, but also includes more comm ...

    SBIR Department of Health and Human Services
  8. PAS-17-064 : Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R43/R44)

    Release Date: 12-02-2016Open Date: 03-05-2017 Due Dates: Multiple Close Date: 09-05-2019

    In the United States (US), it is estimated that more than 5 million people suffer from Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD).  By 2050 this number is forecast to rise to more than 15 million.  Moreover, caring for and treating patients with AD/ADRD is expensive.  Current estimated annual costs for AD/ADRD care and treatment total approximately $20 ...

    SBIR Department of Health and Human Services
  9. PAS-17-065: Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42)

    Release Date: 12-02-2016Open Date: 03-05-2017 Due Dates: Multiple Close Date: 09-05-2019

    In the United States (US), it is estimated that more than 5 million people suffer from Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD).  By 2050 this number is forecast to rise to more than 15 million.  Moreover, caring for and treating patients with AD/ADRD is expensive.  Current estimated annual costs for care and treatment of AD/ADRD total approximately ...

    STTR Department of Health and Human Services
  10. PAR-17-067: Tools for Clinical Care and Management of Alzheimer’s Disease (AD) and its Comorbidities (R43/R44)

    Release Date: 12-02-2016Open Date: 03-05-2017 Due Dates: Multiple Close Date: 09-05-2019

    The principal aim of this SBIR Funding Opportunity Announcement (FOA) is to stimulate research focusing on the development of innovative technologies that would enhance the treatment and clinical management of Alzheimer's disease (AD), Alzheimer's disease-related dementias (ADRD), and their related comorbidities.  Alzheimer's disease (AD) is the leading cause of dementia individuals over the ...

    SBIR Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government